## 36th Annual Meeting

March 6-11, 2010 • JW Starr Pass Marriott Resort & Spa, Tucson, AZ

### Educational Program Schedule

#### THURSDAY, MARCH 11

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 a.m. – 12:30 p.m.</td>
<td>Registration</td>
<td>Arizona Ballroom Foyer</td>
</tr>
<tr>
<td>6:30 a.m. – 7:30 a.m.</td>
<td>Continental Breakfast</td>
<td>Arizona Salon</td>
</tr>
<tr>
<td>8:30 a.m. – 10:30 a.m.</td>
<td>Spouse/Guest Hospitality Suite</td>
<td>Signature Grill</td>
</tr>
</tbody>
</table>
| 7:30 a.m. – 9:30 a.m.  | OCT IN NEURO–OPHTHALMOLOGY PRACTICE [2 CME]                           | Arizona Salons 1–6              

*Moderators: Laura J. Balcer, MD, MSCE and Fiona Costello, MD*

This half-morning symposium will review the current knowledge concerning the use of optical coherence tomography (OCT) in patients with neuro-ophthalmologic disorders. The session will discuss the history of OCT and the evolution of the underlying technology. The currently available and future equipment will be discussed and evaluated. The evidence regarding the use of OCT in the diagnosis and follow-up of optic neuritis, chiasmal lesions, multiple sclerosis and other neurologic diseases will be reviewed. A perspective on the clinical utilization of OCT drawing on experience from its place in glaucoma management will be presented. The potential of OCT for monitoring possible neuro–protective treatment of optic nerve and macular disease will be reviewed.

At the conclusion of the symposium, the attendees should be able to: 1) Describe the principle of OCT and the forms of equipment available to perform the test; 2) Discuss the currently available evidence about the use of OCT in evaluating optic neuritis, MS, chiasmal lesions, and other neuro-ophthalmologic disorders; 3) Explain the lessons available from the use of OCT in management of glaucoma; and 4) Discuss the potential use of OCT in monitoring the effects of therapy of anterior visual pathway disease, including neuroprotective agents.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 a.m. – 7:50 a.m.</td>
<td>OCT Technologies: Past, Present, and What’s New? – Joel Schuman, MD</td>
<td>327</td>
</tr>
<tr>
<td>7:50 a.m. – 8:10 a.m.</td>
<td>OCT in Neurologic Disease – Eric Eggenberger, DO, MSEpi</td>
<td>335</td>
</tr>
<tr>
<td>8:10 a.m. – 8:30 a.m.</td>
<td>Lessons from Glaucoma: Use of OCT in the Clinic and Trials – Joel Schuman, MD</td>
<td>343</td>
</tr>
<tr>
<td>8:30 a.m. – 8:50 a.m.</td>
<td>Linking Axons and Neurons: Unveiling Mysteries of the Macula and Modeling Neuroprotection – Randy Kardon, MD, PhD</td>
<td>369</td>
</tr>
<tr>
<td>8:50 a.m. – 9:05 a.m.</td>
<td>Platform Presentation: Ganglion Cell Layer Volume by Spectralis Optical Coherence Tomography (OCT) in Multiple Sclerosis – Emma Davies, MD</td>
<td>375</td>
</tr>
<tr>
<td>9:05 a.m. – 9:20 a.m.</td>
<td>Evidence Meets Practice: Take–Home Points on OCT – Thomas Hedges, III, MD</td>
<td>377</td>
</tr>
<tr>
<td>9:20 a.m. – 9:30 a.m.</td>
<td>Questions and Discussion</td>
<td></td>
</tr>
<tr>
<td>9:30 a.m. – 10:00 a.m.</td>
<td>Coffee Break</td>
<td></td>
</tr>
</tbody>
</table>
10:00 a.m. - 12:00 p.m.  THYROID EYE DISEASE UPDATE [2 CME]

Moderators: Steven Feldon, MD and Madhu Agarwal, MD

This course will review the latest concepts in the evaluation and treatment of the often vexing disease process of thyroid orbitopathy. The immunology of the condition as well as potential new treatments and their indications will be discussed. Speakers will further discuss newer modalities for assessing disease progression, evaluating strabismus, and surgical and pharmacologic treatment options. A panel discussion will consider these topics, as well as the potential for clinical trial in this area.

At the conclusion of the symposium, the attendees should be able to: 1) Understand the latest diagnostic and assessment tools for thyroid eye disease; and 2) Discuss both medical and surgical treatment options.

10:00 a.m. - 10:30 a.m.  Immunology of Thyroid Eye Disease: New Treatments on the Horizon? – Raymond Douglas, MD, PhD

10:30 a.m. - 10:50 a.m.  Objective Markers for Thyroid Eye Disease (TED) Activity, Severity and Progression – Kim Cockerham, MD, FACS

10:50 a.m. - 11:20 am.  Surgical Techniques for Anatomic Restoration – Raymond Douglas, MD, PhD

11:20 a.m. - 11:40 am.  Ocular Motility in Thyroid Eye Disease -Evaluation and Surgery – Steven Feldon, MD

11:40 a.m. - 12:00 p.m.  Panel Discussion: Impediments to Formulating a Meaningful Clinical Trial

12:00 p.m.  Meeting adjourns
LEARNING OBJECTIVES

• The attendee will be able to describe the basic principles of optical coherence tomography.

• The attendee will be able to explain how OCT can be used in the detection of ocular diseases.

• The attendee will know the utility and potential utility of OCT in the assessment of longitudinal change in diseases of the eye.

CME QUESTIONS AND ANSWERS

1. What is the basic physical principle underlying optical coherence tomography (OCT)?

2. How can OCT be used to detect eye disease, and is there any evidence that it can do so?

3. How can OCT be used to assess change over time in eye disease?

KEY WORDS

• Optical Coherence Tomography (OCT)

• Optic Nerve Head (ONH)

• Retinal Nerve Fiber Layer (RNFL)

• Macula

• Ganglion Cell Complex (GCC)

INTRODUCTION

The development of optical coherence tomography (OCT) began with a team comprised of clinician–scientists and a physicist at Massachusetts Eye and Ear Infirmary (MEEI), Harvard University and engineers at the Massachusetts Institute of Technology (MIT). Remarkably, one member of this group was a graduate student, one a postdoctoral fellow, and another was a predoctoral fellow. OCT actually began as optical coherence domain ranging (OCDR), essentially a single A-scan in what we now know as OCT. OCDR was being developed by James Fujimoto and Carmen Puliafito for corneal ranging. Joel Schuman was a fellow in Puliafito’s laser laboratory at MEEI and David Huang an MD, PhD student in the Harvard–MIT Health Sciences Technology (HST) program, working in Fujimoto’s laboratory at MIT. Eric Swanson was an engineer at MIT–Lincoln Laboratories, Charles Lin a physicist in Puliafito’s lab and William Stinson a preresidency fellow working in Puliafito’s lab as well. These seven people were the key persons involved in the development of this technology.

Joel Schuman, while working on other projects in the laser laboratory, became aware of the OCDR corneal ranging target. It occurred to Schuman that the near infrared wavelength of OCDR would be able to safely measure retinal thickness, and would perhaps be useful for measuring retinal layers. After discussing this idea with Puliafito, Schuman pursued the concept together with Fujimoto and Huang. Schuman, Huang, Lin and Stinson did the very first retinal ranging experiments in James Fujimoto’s laboratory at MIT.

David Huang, while an MD–PhD student, had the insight that an OCDR A-scan was similar to an ultrasound A-scan, and that creating a tomographic cross-sectional image similar to an ultrasound B-scan would be possible. The technology was refined to create tomography, and was renamed Optical Coherence Tomography (OCT). In 1991 the first scientific paper regarding OCT was published, describing the use of an optical detection technique called low coherence interferometry to acquire cross-sectional images of the peripapillary region of the human retina ex vivo. Low coherence tomography refers to the detection of light that has been split, reflected off of an object of interest and a reference mirror and recombined. This recombination produces an interference pattern with an amplitude proportional to the reflectivity of the corresponding location (same optical path length) within tissue of interest. Individual axial scans, or A-scans, are
acquired at a given location in tissue and correspond to a reflectivity profile in depth. Multiple neighboring A-scans can be acquired to build up a B-scan that represents an optical cross-section of the tissue.

OCT was described in vivo in 1993 and quickly used in human subjects as a research tool to investigate retinal and glaucomatous abnormalities. During this time the technology was transferred to industry. The OCT patent was granted in 1994 to Fujimoto, Huang, Lin, Puliafito, Schuman and Swanson, and was licensed by what is now Carl Zeiss Meditec, Inc. (Dublin, CA), allowing the creation of a device that could be broadly used for patient care.

The first commercial system became available in 1996 and was a time-domain OCT system (TD-OCT). This means A-scans are acquired by moving the interferometer’s reference mirror, which changes the reference path length and enables the detection reflectivity from different depths in a given structure. Hence, in TD-OCT imaging, the time of flight of the light reflected from the retinal structures determines the OCT measurements. The commercial time-domain OCT system has an axial resolution of approximately 10 μm.

The first commercial two iterations of OCT were not particularly successful, in part because of the novelty of the technology, but also because systems were big, slow and difficult to use. This changed in 2002 with the introduction of Stratus OCT. The Stratus system acquired 400 A-scans per second, compared with 100 per second in prior versions. Stratus OCT also had a normative database, making clinical use considerably more practical, and the system was now ergonomically designed. Finally, a billing code for scanning computerized ocular diagnostic imaging was introduced around the time that Stratus came to market. All of these factors contributed to the rapid adoption of the technology; by 2008, 10,000 OCT devices were in worldwide clinical use.

OCT underwent further evolution with the clinical availability in 2006 of spectral-domain OCT (SD-OCT). SD-OCT introduced in 2006 was 40–60 times faster than TD-OCT, allowing the collection of large amounts of clinical data, permitting increased scan densities and three-dimensional imaging. SD-OCT refers to the measurement of tissue thickness using not time of flight but reflected wavelengths (frequencies). Using SD-OCT, an entire A-scan can be collected simultaneously, and the optical frequencies analyzed using fast Fourier transformation and mathematical algorithms to create a tomographic image and determine depth information, converting from the frequency domain to the time domain. Because optical frequencies from different depths are detected at once and used to determine the spatial locations of reflections in the A-scans, a moving reference mirror is not required: conversion from the frequency domain to the time domain occurs after acquisition. This means SD-OCT systems can acquire A-scans much faster than time-domain systems. SD-OCT systems have recently been commercialized by several companies, and most of these systems have an axial resolution of approximately 3.5 – 6 μm and acquisition speeds of 24,000 – 55,000 A-scans per second. Axial resolution improvements in these systems can be attributed to broader bandwidth light sources.

HEALTHY EYES

This section provides representative ocular OCT images, both time-domain and spectral domain, from healthy subjects. Figure 1a shows a representative SD-OCT image through the macular region of a healthy subject, while the Figure 1b shows a representative TD-OCT image from the same subject. Note that the time-domain image contains 128 Ascans and the SD-OCT image contains 1000 A-scans; however, the TD-OCT image required 0.32 seconds to acquire, while the SD-OCT image, with eight times more Ascans, took 0.04 seconds.

FIGURE 1: (a) Vertical SD-OCT cross-section through the macula of the same subject. The white box with vertical line indicates the orientation of SD-OCT image. (b) Vertical TD-OCT cross-section through the macula.

Figure 2 shows spectral domain (left panel) and time-domain (right panel) OCT retinal nerve fiber layer (RNFL) assessments. With time-domain devices, a 3.4-mm circular scan centered on the optic nerve head (ONH) is used to assess peripapillary RNFL thickness. Typically, three OCT scans (with 256 A-scans per scan) are acquired in succession, the RNFL is segmented, and thickness measurements along the scan are compared to a normative database. Using spectral-domain three-dimensional tissue volumes from around the optic nerve, one can reconstruct the RNFL peripapillary scan by resampling the tissue volume along a 3.4 mm circle centered on the ONH. An extracted RNFL scan can be seen in Figure 2, bottom left. Above it, an RNFL thickness overlay on a normative database is shown along with clock-hour and quadrant RNFL thickness measurements. One peripapillary TD-OCT scan, with RNFL segmentation (white line), is shown in Figure 2, bottom right. Above it lie the normative database with an overlay of RNFL thickness and clock-hour and quadrant RNFL thickness measurements.
In SD-OCT, after multiple B-scans are acquired in raster fashion and a three-dimensional volume of tissue is acquired, en-face (OCT fundus) images can be generated by summing intensity values along the z-direction (in depth). An example SD-OCT fundus image through the macular region of a healthy subject is seen in Figure 3.

When three-dimensional tissue volumes have been acquired around the optic nerve head region using SD-OCT, RNFL thickness maps can be created by segmenting the RNFL in each frame of the volume, excluding the optic nerve head region. This provides easy visualization of areas of thinning around the optic nerve. Example RNFL thickness maps from a healthy subject can be seen in Figure 4.

In addition to posterior segment imaging, images of the cornea and anterior chamber can be acquired with OCT. Figure 5 shows a horizontal TD-OCT image through the cornea of a healthy subject. Figure 6 shows an anterior chamber TD-OCT image from the same subject.
GLAUCOMA

A 58-year-old woman with a history of primary open angle glaucoma presented with an IOP of 30 in the right eye (VA 20/20). Visual field testing showed a superior arcuate defect, with a glaucoma hemifield test outside normal limits, mean deviation of -1.25 dB, and pattern standard deviation of 4.37 dB (Figure 7). Widespread inferior nerve fiber layer thinning can be seen in the SD-OCT RNFL thickness map (Figure 8). Figure 9, top, shows clock hour and quadrant thicknesses from SD-OCT (left panel) and TD-OCT (right panel). A comparison to a normative database is shown below the segment measurements. Both spectral- and time-domain measurements show inferior thinning of the RNFL, as indicated by red quadrant and clock hour segments. Looking at individual spectral-domain and time-domain OCT cross sections (bottom left and bottom right, respectively), thinning of the RNFL can be seen (arrows). Note that the white line outlining the RNFL in the time-domain image indicates segmentation of the RNFL; this line is not present in the spectral-domain image. In addition, the spectral-domain image has not been flattened using image filtering techniques while the time-domain image has.

FIGURE 7: Visual field test showing a superior arcuate defect from a patient with primary open angle glaucoma.

FIGURE 8: RNFL thickness map of patient with primary open angle glaucoma showing inferior thinning of the RNFL (map created from 200 x 200 A-scans, 6×6 mm region around the optic nerve head). The uniform blue region towards the center of the image represents the optic nerve head while black region is the result of RNFL detection algorithm failure.

AGE-RELATED MACULAR DEGENERATION

Figure 10 shows a fundus photograph and slow macular (512 A-scans) TD-OCT scan from an 84-year-old female with exudative age-related macular degeneration; she had 20/40 vision in the right eye. Drusen and RPE changes were noted upon clinical examination. The fundus photograph (Figure 10a) shows numerous drusen in the macular region. Similarly, irregularities in the RPE can be seen in the horizontal OCT crosssection though the macular region (Figure 10b, arrows).

FIGURE 10: (a) Fundus photograph of age-related macular degeneration patient with drusen (b) Horizontal TD-OCT scan (512 A-scans). Arrows indicate areas that are likely drusen.

FIGURE 9: (Left) SD-OCT RNFL thickness clock-hour and quadrant measurements (top), comparison to normative database (middle), and resampled 3.4-mm RNFL B-scan (bottom) in patient with primary open angle glaucoma and inferior RNFL loss. (Right) TD-OCT RNFL thickness measurements (top), comparison to normative database (middle) and 3.4-mm RNFL peripapillary scan (bottom). Both images were acquired from the same subject, same day.
MACULAR HOLE
A 72-year-old male presented with a distorted vision in the right eye (VA 20/200) and 20/50 vision in the left eye. Both spectral-domain and TD-OCT images showed a large macular hole in the right eye with posterior hyaloid partially attached to edge of the hole (Figure 11, spectral-domain horizontal and vertical cross-sections on left and timedomain horizontal and vertical cross-sections on right). Small cystoid changes with a vitreous traction were seen in the left eye along with posterior hyaloid traction in the foveal center (Figure 12). Three-dimensional reconstructions of the thickness maps of the macular region are also shown (Figure 11 and 12, top) and were created by segmenting three-dimensional data volumes (200 x 200 A-scans in a 6 x 6 mm region of the retina) from the ILM to the RPE. The blues lines on each thickness map correspond to the location of the horizontal spectral-domain cross-sections (1000 A-scans each), while the purple lines correspond to the location of vertical cross-sections (1000 A-scans).

FIGURE 11: Right eye (Top) Three-dimensional reconstruction of macular region showing foveal thickening (red) that corresponds to the location of a macular hole and corresponding edema (Middle and Bottom, left) Horizontal and vertical SD-OCT (1000 A-scans) cross-sections through the macular hole (Middle and Bottom, right) Horizontal and vertical TD-OCT (512 A-scans) cross-sections through the macular hole.

FIGURE 12: Left eye. (Top) Three-dimensional reconstruction of macular region showing slight foveal thickening (green) that corresponds to the location of small cystoid changes (Middle and Bottom, left) Horizontal and vertical SD-OCT (1000 A-scans) crosssections through the macular (Middle and Bottom, right) Horizontal and vertical TD-OCT (512 A-scans) cross-sections through the macula.

BRANCH RETINAL VEIN OCCLUSION
Figure 13a shows a late-phase angiograph from an 82-year-old male with branch retinal vein occlusion in the right eye. He presented with a visual acuity of 20/400 and clinical examination showed hemorrhage and macular edema in the right eye. A slow macular (512 A-scans) horizontal TD-OCT image showed clinically significant macular edema (Figure 13b).

FIGURE 13: (a) Late-phase angiograph showing branch retinal vein occlusion (b) Horizontal TD-OCT image (512 A-scans) through the macular region showing edematous changes.

FIGURE 14: (a) Three-dimensional reconstruction of macular region showing macular puckering (b) Horizontal SD-OCT (1000 A-scans) and (c) time-domain (512 A-scans) OCT images through the macula, with arrows indicating epiretinal membrane.

MACULAR PUCKER
A 60-year-old woman with 20/70 vision in the left eye showed a pronounced epiretinal membrane with posterior vitreous detachment. A three-dimensional reconstruction of the macular thickness map illustrates the extent of macular puckering (Figure 14a). The epiretinal membrane can be seen in individual horizontal spectral-domain (Figure 14b) and time-domain (Figure 14c) OCT images (arrows).

FIGURE 14: (a) Three-dimensional reconstruction of macular region showing macular puckering (b) Horizontal SD-OCT (1000 A-scans) and (c) time-domain (512 A-scans) OCT images through the macula, with arrows indicating epiretinal membrane.
DIABETIC MACULAR EDEMA

Figure 15 (a) and (b) show a fundus and red-free photograph, respectively, from a 65-year-old male with moderate nonproliferative diabetic retinopathy and clinically significant diabetic macular edema in the right eye. He presented with 20/160 vision in this eye. Scattered blot hemorrhages and hard exudates can be seen in the fundus photograph, and microaneurysms in the red-free photograph. A SD-OCT macular thickness map (200 x 200 A-scans covering 6x6 mm region, segmented from the ILM to the RPE) superimposed on a fundus photograph (Figure 15c) shows a region of thickening that corresponds to the macular edema, with thicker areas represented as hotter colors. Horizontal (Figure 15d) and vertical (Figure 15e) spectral-domain crosssectional OCT images show the extent of fluid accumulation in the macular region.

FIGURE 15: (a) Fundus photograph of patient with diabetic retinopathy and clinically significant macular edema. (b) Red-free photograph. (c) SD-OCT thickness map of macular region superimposed onto fundus photograph, with thicker areas white/red. (d) Horizontal and (e) vertical SD-OCT images (1000 A-scans each), the location of each corresponding to the blue and purple lines on the macular thickness map.

POTENTIAL DIAGNOSTIC POWER

Since its commercialization in 1996, OCT has increasingly become a valuable tool for ophthalmologists. Posterior segment imaging has improved the quantification of RNFL damage in glaucoma and the visualization of changes due to age-related macular degeneration, macular hole, epiretinal memer and macular puckering, macular edema and more. In addition, anterior segment imaging allows clinicians to monitor patients after LASIK (not shown here) and corneal injury, and provides a non-invasive alternative to ultrasound biomicroscopy for anterior chamber imaging.

While OCT offers several advantages to clinicians, certain limitations need to be kept in mind. This technique, especially spectral-domain imaging, is still rather new and longitudinal studies are required to evaluate its objective monitoring capabilities. In addition, high-speed imaging is very sensitive to eye motion and large movements may make measurements inaccurate. Fortunately, however, solutions to these restrictions are currently being pursued by several research groups.

In sum, OCT offers clinicians a new perspective on structural damage caused by disease. This may lead to enhanced diagnostic power — not only through objective quantification but through synergy with other methods of evaluation that are presently available to clinicians.

CME ANSWERS

1. OCT is based on interferometry

2. Measurements of various ocular structures demonstrate differences in disease and health. There are numerous articles showing the usefulness of OCT in disease detection for glaucoma and other optic neuropathies, macular degeneration and other retinal diseases, as well as diseases of the anterior segment and anterior chamber angle.

3. Change can be measured in the RNFL, macula and optic nerve head using software algorithms, some of which exist already and others in development. The relevant tissue should be evaluated when investigating longitudinally.
REFERENCES


LEARNING OBJECTIVES
The attendee will be able to:

1. Understand OCT as it applies to optic neuropathy-related neurologic diseases such as MS.
2. Understand OCT applications to CNS diseases associated with disc edema.
3. Understand relationships between OCT measures and other CNS measures including clinical optic nerve function.

CME QUESTIONS
1. OCT works by:
   a. light reflectivity
   b. echo location
   c. birefringence of the retinal axons
   d. xray imaging
   e. magnetic imaging
2. OCT has demonstrated retinal nerve fiber loss in which of the following conditions:
   a. optic neuritis
   b. MS
   c. Alzheimer’s disease
   d. NAION
   e. All of the above
3. OCT is an emerging non-invasive technology that at present is a useful tool in the GROUP analysis of neuro-ophthalmic conditions, rather than the basis for INDIVIDUAL clinical decisions. True or False

KEY WORDS
1. OCT
2. Optic Neuritis
3. Multiple Sclerosis
4. Papilledema

INTRODUCTION
Optical coherence tomography (OCT) has evolved dramatically since the first reports of this technology in 1991, and has become an integral part of the ophthalmology evaluation. In addition to providing an indispensible service for the retina physician, the ability to quantify the retinal nerve fiber layer has begun to change neuro-ophthalmic practice. In this regard, OCT has the potential to change qualitative, subjective descriptive reporting into reproducible quantitative science.

Quantification of the RNFL has several clinical applications, including numerous diseases of the optic nerve, both in documentation of edema and quantification of optic atrophy; OCT has also become a viable study outcome in treatment trials. This review will focus on current OCT applications as they apply to neuro-ophthalmic clinical practice.

RETINAL IMAGING METHODOLOGIES
In addition to OCT, commercially available retinal imaging devises also include Heidelberg Retinal Tomography (HRT), and scanning laser polarimetry (GDx). Each of these instruments has inherent advantages and disadvantages, and results obtained from 1 instrument do not translate into results from another imaging technique. The Heidelberg Retina Tomograph (HRT) is a confocal laser scanning system to acquisition three dimensional retinal images. GDx relies on birefringence of the retinal ganglion cell axon microtubules and filaments. Monteiro and Moura compared GDx with variable corneal compensation (VCC) against TD-OCT in patients with band atrophy (BA) from chiasmal compression, and reported GDx appeared to underestimated the temporal quadrant by an average of 22µm; conversely, Zaveri et al found OCT and GDx-VCC equally able to measure RNFL thickness in MS patients experiencing acute optic neuritis; by virtues of assessing retinal ganglion cell axon microtubule density, GDx changes appeared earlier than OCT–demonstrable RNFL thinning. The remainder of this review will focus on OCT as the most common methodology employed in neuro-ophthalmic practice.

OCT METHODOLOGY
Time-domain OCT (TD-OCT), the 3rd generation instrument, is able to record a series of 512 x 1024 A-scan images within 2 seconds with approximately 10µm resolution. Several studies have demonstrated TD-OCT’s reproducibility in assessing the RNFL thickness in normal eyes, glaucoma, and various non–glaucomatous optic
neuropathies. The next generation of OCT, Spectral-domain OCT (SD-OCT), has significantly improved the speed of image acquisition; the SD-OCT captures approximately 27,000 scans per second with a resolution of 5µm, and has the ability to form a 3-dimensional map of the retina and optic nerve, allowing more accurate distinctions between retinal layers. In addition, SD-OCT automatically centers the scan on the optic disc with the use of optic nerve landmarks to decrease scan — rescans variability. Although measurements with the TD-OCT and SD-OCT instruments correlate well, the RNFL and retinal thickness results are not interchangeable.

OCT VS Histology
Blumenthal et al compared OCT–derived RNFL measurements to histology–derived measurements (exenterated orbit secondary to an infiltrative squamous cell carcinoma), and reported OCT outcomes mirrored the histology, but actual measurements differed by 10–40µm. This discrepancy likely reflects identification of the RNFL layers via staining techniques versus optical reflectance.

FACTORS INFLUENCING SCAN ACCURACY
Several factors influence the quality of OCT images. The 3.4 mm laser reticule must be centered on the optic nerve; decentered scans preferentially affect quadrant thicknesses, especially the vertical quadrants, while total RNFL remains relatively stable. Surprisingly, use of the OCT scan tracking coordinates only provided a statistically significant effect on the temporal quadrant. Signal strength also positively correlates with the observed RNFL thickness; many studies require signal strength of 7. Pupil size is not generally a significant factor as long as size is ≥ 3mm. Lens opacities are inversely correlated with the measurement of RNFL thickness (effect size < 12%); similarly, contact lenses use is associated with decrease in signal strength (7.8 to 7.1; P=0.011) and the measured average RNFL thickness (average RNFL 105.3 to 102.8µm; P=0.001).

OCT IN CNS DISEASE/OPTIC NEUROPATHIES
Anterior Ischemic Optic Neuropathy (AION)
AION is a disease characterized by disc edema at onset with subsequent optic atrophy. Contreras and colleagues used OCT to study 27 patients with NAION at baseline, 6–weeks; and 3, 6, and 12 months after onset. The initial mean RNFL of 201µm represented a 96.4% increase relative to the fellow eye. Percentages of RNFL loss 3, 6, and 12 months after onset were 38.9%, 42.3%, and 43.9%, respectively. Regression analysis revealed a 2–dB decrease in visual field function for every 1-µm of mean RNFL thickness loss, and a 1-line drop in Snellen visual acuity for every 1.6µm deficit.

Bellusci et al documented RNFL edema followed by thinning in the superior optic nerve among acute NAION patients with inferior altitudinal defects; conversely, patient with diffuse visual field (VF) loss had extensive RNFL thinning. Temporal quadrant RNFL thinning (papillomacular fibers) correlated with central field defects. Chan et al used OCT to investigate the optic disc in 22 NAION patients; smaller cups and C:D ratios were more common in NAION eyes compared to control eyes; additionally, a smaller cup was present in the non–affected fellow eye of NAION patients (C:D 0.103) compared to the affected NAION eye (C:D 0.135; P=0.04), suggesting a small degree of cup enlargement after NAION.

These studies indicate that OCT–measured RNFL values correlate with the topographical representation of visual field defects in eyes with NAION. Further, reduced RNFL values can help predict recovered visual function in NAION patients.

Optic Neuritis (ON) & Multiple Sclerosis (MS)
Several investigators have demonstrated RNFL loss in MS patients even without a history of optic neuritis, while superimposed optic neuritis produces additional RNFL decline. There is a clinical–OCT paradox concerning optic neuritis, similar to the MRI–clinical paradox within MS. MRI T2 lesion load does not correlate with overall neurologic function, with MS patients often exhibiting MRI lesions out of proportion to their clinical condition (especially as assessed by the EDSS). Similarly, OCT RNFL loss appears out of proportion to the clinical visual assessments. Although the majority of patients lose RNFL following an episode of optic neuritis, most recover “normal” visual function (despite the patients’ perception that the ‘recovered’ eye is not normal). Costello et al documented an OCT injury threshold of 75µm before a linear decline in visual field was apparent. Several studies have investigated RNFL quadrant data after optic neuritis, and there appears to be a predilection for the infero–temporal quadrants.

Costello et al investigated OCT findings in CIS optic neuritis. There was no significant difference in RNFL thickness between CIS progressing to MS versus CIS without MS at 2 years follow up; however, progressive RNFL thinning was more apparent in CIS patients progressing to MS.

OCT has been used to investigate MS subtypes; RNFL loss is generally greater in progressive MS than RRMS (somewhat duration of disease dependent).

Neuromyelitis Optica (NMO)
In most reports, NMO is associated with greater RNFL loss than optic neuritis or MS. De Seze et al reported RNFL thickness of 29 NMO patients had significantly reduced RNFL values (77.9 µm ) compared to controls. OCT is not specific enough to distinguish NMO form ON/MS, but NMO should be considered in ON patients with poor recovery, or dramatic RNFL thinning <50µm.
Patients with idiopathic intracranial hypertension (IIH) typically present with headache, pulsatile tinnitus, transient visual obscurations, and papilledema usually with relatively preserved visual acuity. Intuitively, we expect elevated RNFL values at presentation when optic disc edema is maximal, and decreasing RNFL elevation with effective treatment.

Rebolleda and Munoz-Negrete studied 22 PTC patients, and noted the initial increase in RNFL correlated well with visual field mean deviation (MD) (P=0.002) and pattern standard deviation (PSD; P=0.013). At 1 year follow-up, perimetry demonstrated a 0.6dB MD decline with a 10µm RNFL decrease. It should be noted that OCT alone is unable to distinguish resolving edema from emerging RNFL decrease. It should be noted that OCT needs to be incorporated into the remainder of the clinical exam. Additional information on OCT in IIH will emerge from the OCT substudy of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).

Optic Nerve Head Drusen
Johnson et al applied the TD-OCT “fast optic disc” protocol to differentiate disc drusen from disc edema. Drusen appeared more “lumpy-bumpy” with RNFL thinner than 86µm nasally in contrast to the smooth and elevated contour of true disc edema.

Compressive Optic Neuropathy (CON)
Danesh-Meyer et al investigated OCT’s ability to predict visual recovery from CON. Thirty five patients with various etiologies of CON were evaluated with OCT and visual fields pre- and post-surgical decompression. The patients were divided into 2 groups: “normal” RNFL and “thin” RNFL (defined as pre-op RNFL <97.5% of normal values). Patients with reduced VA and VF but normal RNFL thickness had significant improvement of VA (mean of 20/40 to 20/25; P=0.028) post-decompression than those with “thin” RNFL (20/80 to 20/60; P=0.177). Although the mean improvement in the “thin” RNFL group of 2 lines was statistically insignificant, this degree of improvement may well be clinically significant. The analysis found an increased likelihood of post-op improvement with a thicker pre-op RNFL until approximately 85µm, after which there was no additional benefit was observed; this likely reflects the fact that patients with RNFL of 85µm have relatively preserved visual function. While pre-op measurements of RNFL do not necessarily change our management of patients with CON, such studies enhance our ability to predict visual outcome post decompression in CON.

Hereditary Optic Neuropathies/Leber Hereditary Optic Neuropathy (LHON)
Leber hereditary optic neuropathy (LHON) is a mitochondrially inherited degeneration of retinal ganglion cells and their axons that leads to an acute or subacute loss of central vision. Affected patients are predominantly males, mutations in the mitochondrial genome from their mother. LHON is usually due to one of three pathogenic mitochondrial DNA (mtDNA) point mutations: at nucleotide positions 11778 G to A, 3460 G to A and 14484 T to C, respectively, in the ND4, ND1 and ND6 subunit genes of complex I of the oxidative phosphorylation chain in mitochondria. Clinically, patients may develop often acute onset visual loss in one eye, followed by fellow eye involvement months to weeks later. Vision loss typically occurs in young adulthood. In the acute stage, the affected eye demonstrates telangelatic and tortuous peripapillary vessels; and with time, optic atrophy ensues.

Seo et al. studied RNFL in LHON patients with the 11778 and 14484 mutations. Patients were divided into early (≤6 months) and late (>6 months) categories. In the late stage, the RNFL thickness was greater in the 14484 group (average RNFL 81µm) compared to the 11778 (average RNFL 65.6µm; P=0.02), thus supporting severe atrophy in the late 11778 group. Comparisons between the 2 mutations in the early stage may be misleading, since there can be considerable variability within this time frame as thinning occurs. Overall, these OCT findings are in agreement with the clinical impression that the 11778 mutation is associated with worse visual outcome than the 14484 mutation.

Savini et al used OCT to study RNFL thickness in unaffected carriers with LHON mutations. Sixty-six unaffected carriers (44 females and 22 males) were analyzed and compared with an age-matched control group of 70 patients (40 females and 30 males). As compared to the control group, unaffected male carriers showed thicker RNFL measurements in the temporal and inferior RNFL quadrants and in the 360 degrees average measurements. These differences reached statistical significance in subjects carrying the 11778 mutation, whereas only a trend was detected in those with the 3460 mutation. Unaffected female carriers had an increased thickness in the temporal quadrant when compared with the control group (P = 0.003). The increase in temporal sectors was statistically significant in females with the 11778 mutation, whereas a trend was detected in those with the 3460 mutation. A thickening of the temporal fibers was detected in all subgroups of unaffected carriers.

Migraine
Martinez et al used OCT to study 70 patients with migraine, and noted a significant RNFL reduction in the temporal quadrants of migraineurs compared to healthy controls; additionally, the RNFL in migraine with aura (average RNFL 96.5µm) was significantly less than migraine without aura (average RNFL of 102.9µm; P=0.0189). Significantly thinner RNFL was found in patients with migraine ≥15 years. These investigators found a correlation between RNFL thickness and migraine disability assessment (MIDAS) scores.
Neurodegenerative disease/Alzheimer Disease
There is both histologic and retinal imaging evidence of retinal ganglionic cell (RGC) in patients with Alzheimer disease (AD). Danesh–Meyer et al used HRT scanning laser ophthalmoscopy (SLO) to investigate 40 patients with AD compared to age– and sex–matched controls, and found that clinical and SLO vertical cup–to–disc ratio was significantly different between the groups (AD 0.4, control 0.27–0.31); additionally, these authors reported decreased rim volume, RNFL thickness and rim area in AD compared to controls.

CONCLUSION
OCT has enhanced our assessment, management, and understanding of neuro–ophthalmic diseases, and has potential to further our understanding of other CNS–based diseases. OCT has the advantages of reproducibility, ease of use, non–invasive nature and relatively low cost, makes it an asset to several clinical situations. With its advancement into spectral domain, OCT has wide use in evaluating the optic nerve and the visual system.

CME ANSWERS
1. A
2. E
3. True

REFERENCES
7. OCT and PVEP examination in eyes with visible idiopathic optic disc drusen. 2006;223(12):993–6.


123. Seo JH, Hwang JM, Park SS. Comparison of retinal nerve fibre layers between 11778 and 14484 mutations in Leber’s hereditary optic neuropathy. Eye. 2009 Feb 27. [Epub ahead of print]


LEARNING OBJECTIVES

1. The participant will be able to describe the two types of optical coherence tomography devices.
2. The participant will be able to explain the advantages of Spectral-Domain Optical Coherence Tomography in comparison to Time-Domain Optical Coherence Tomography.
3. The participant will be able to describe five different scenarios where OCT would be clinically useful in glaucoma diagnosis and management.

CME QUESTIONS

1. What are the most clinically relevant parameters collected from an OCT scan for glaucoma?
2. Name the three main scans from time domain OCT.
3. Name 4 advantages of Spectral-Domain Optical Coherence Tomography in comparison to Time-Domain Optical Coherence Tomography

KEY WORDS

- Optical Coherence Tomography (OCT)
- Time-Domain Optical Coherence Tomography (TD-OCT)
- Spectral-Domain Optical Coherence Tomography (SD-OCT)
- Retinal Nerve Fiber Layer (RNFL)
- Circumpapillary Scan
- Ganglion Cell Complex (GCC)
- Glaucoma Progression Analysis (GPA)
- Visual Field Index (VFI)
- Pre-perimetric
- Central Island

ABSTRACT

Glaucoma is the second leading cause of blindness worldwide. It is characterized by the accelerated death of retinal ganglion cells and presents as progressive functional damage to the visual field. There is no formal screening method for glaucoma. Disease detection is solely dependent on the clinical capabilities of the eye care provider. The first-line diagnostic tools for identifying glaucoma are clinical examination with direct or indirect ophthalmoscopy and/or stereoscopic optic nerve head photographs. Unfortunately, these tools are prone to high intra- and inter-observer variability. Recently, a number of imaging devices have been introduced with the goal of early detection and quantification of structural glaucomatous changes in the retinal nerve fiber layer and optic nerve head. One of the commercially available glaucoma imaging devices is optical coherence tomography (OCT). OCT generates cross-sectional and three-dimensional images of retinal structures. Its application in glaucoma diagnostics and monitoring will be discussed in this chapter.

INTRODUCTION

Glaucoma is the second leading cause of blindness worldwide. It is characterized by the accelerated death of retinal ganglion cells and presents as progressive functional damage to the visual field. The World Health Organization (WHO) has projected this disease to affect 60.5 million individuals by the year 2010, leaving 8.4 million blind. With the world’s aging population, the burden of disease is predicted to grow exponentially, affecting 80 million people by 2020.

With this understanding, the WHO has made it a priority eye disease to address with their program Vision 2020, which aims to prevent avoidable blindness. One of their specific objectives is to develop adequate training methods in the diagnosis of glaucoma, as early intervention has been shown to slow disease progression and preserve functional sight. The NIH National Eye Institute has also set improved glaucoma diagnostic measures as a part of their National Plan for Eye and Vision Research.

Unfortunately, early detection of glaucoma remains a challenge. No symptoms appear until there is advanced retinal ganglion cell death and visual field loss. Estimates of undiagnosed glaucoma range from 40 to 90%, with higher percentages found in underdeveloped nations.

There is no formal screening method for glaucoma. Disease detection is solely dependent on the clinical capabilities of the eye care provider. The first-line diagnostic tools for identifying structural changes in glaucoma are clinical examination with direct or indirect ophthalmoscopy and/or stereoscopic ONH photographs. These tools are mostly qualitative thus prone to high intra- and inter-observer variability. The functional
damage caused by glaucoma which causes characteristic patterns of VF loss is often quantified through the use of standard automated perimetry (SAP). SAP is a threshold test that determines the eye’s sensitivity to light throughout the central visual field (VF). This commonly used clinical test has a high test–retest variability, and multiple VF tests are required to confirm damage.10,11. Also, significant structural loss may occur before changes are detected by VF.12

A number of ocular imaging devices have been introduced which provide reproducible quantification of the retinal nerve fiber layer (RNFL) and ONH. The commercially available glaucoma imaging devices (GIDs) include: optical coherence tomography (OCT), confocal scanning laser ophthalmoscopy (CSLO) and scanning laser polarimetry (SLP).

Using the best parameters of each GID has been shown to have specificity and sensitivity similar to that of glaucoma experts in detecting glaucomatous ONH abnormalities.40,41. Studies directly comparing these three technologies have not found significant differences in their diagnostic ability.42-46. In 2007, the American Academy of Ophthalmology suggested that information from imaging printouts is best used in conjunction with other clinical parameters.47

**COMMERCIAL TYPES OF OCT**

**TD–OCT**
- Stratus (CZMI)

**SD–OCT**
- Cirrus (CZMI)
- Spectralis (Heidelberg Engineering, Heidelberg, Germany)
- RTView (Optovue, Fairmont, CA)
- TopCon (Topcon Medical Systems, Inc, Paramus, NJ)
- Bioptogen (Research Triangle Park, Durham, NC)

**FEATURED HIGHLIGHTS OF OCT DEVICES**

When deciding on an device to use in the clinic or in research, consider that different instruments have different special features which make them unique.

Various imaging devices emphasize:

- Tracking to control for eye motion.
- 3–Dimensional reconstruction.
- Advanced visualization with cube data
- Averaging scan data to make for a visually appealing image.
- Fundus image either red-free or CSLO, which provides information about orientation.
- Quantification of various parameters.
- Comparison to a normative database to use clinically.
- A variety of scan patterns allowing for multiple means of visualizing any pathology.
- Automatic registration within a cube of data allowing for more accurate change analyses.

**OCT SCAN PATTERNS**

**TD–OCT**
- Peripapillary Circle Scan
  - This is relevant in glaucoma as it is a robust indicator of the nerve fiber layer thickness.
- ONH
  - Provides cup and disc parameters.
- Macula
  - This is an alternative to the circle scan which provides a statistically significant correlation with glaucoma.
  - Note: Correlation r=.52 between overall mean macular thickness and peripapillary RNFL thickness.
In a longitudinal study published in 2005 by Wollstein, et al., OCT sensitivity using RNFL thickness was higher than that of SAP. [Reference]

**SD-OCT**
- 3-Dimensional Cube (multiple B-scans compiled)
  - Post-processing allows a misaligned scan to be fixed, removing a limitation of TD-OCT.
  - Increased reproducibility in comparison with TD-OCT [Reference: Kim JS, Br J Ophthalmol 2009]
  - Faster speed in comparison with TD-OCT reduces the number of motion artifacts

**CASE 1: NORMAL EYE**
This was a 45 year old Caucasian man with hypothyroidism and no ocular disease. Best corrected visual acuity in the left eye is 20/16 wearing a prescription of −2.00+1.50×174, intraocular pressure (IOP) was 12 millimeters of mercury (mmHg), and pachymetry showed a central corneal thickness (CCT) of 586. The anterior chamber was normal, and the dilated fundus exam revealed a normal appearing ONH with no other abnormalities (Fig. 1). Humphrey visual fields (HVF) were full (Fig. 2) and showed no progression over the span of 5 years (Fig. 3).

Imaging with OCT, both TD (Fig. 4–9) and SD (Fig. 10–15) revealed structures with parameters within the normal distribution. Confocal scanning laser ophthalmoscopy (CSLO) and scanning laser polarimetry (SLP) confirmed normal ONH parameters (Fig. 17 and 18, respectively).

**FIGURE 1**: Normal color photo (left) and red-free photo (right) of a normal optic nerve head. The white arrow points to the normal coloration of the nerve fiber bundles in a red-free photo.

**FIGURE 2**: HVF – Normal gray scale (left) and pattern deviation (right).

**FIGURE 3**: HVF – VFI graph over 5 years showing no progression.

**FIGURE 4**: Stratus OCT - Circumpapillary B scan with excellent signal strength showing a normal retinal nerve fiber layer thickest in the superior and inferior regions.

**FIGURE 5**: Stratus OCT Infrared Photo — Circumpapillary scan properly placed around the ONH (left) and off-centered, displaced nasally (right).
FIGURE 6: Stratus OCT circumpapillary thickness profiles for properly placed (A, B) and nasally displaced (C, D) scans compared with normal distribution percentiles. Note that the “double hump” pattern in C and D is spread apart. This changes the thickness, although remaining in the normal distribution.

FIGURE 7: Well-centered Stratus OCT macula raster scan. (A) Infrared fundus image. (B) Normal vertical retinal B scan. Note the paucity of reflectance centrally at the foveal dip. (C) Thickness chart — overall retinal thickness compared to a normative database. (D) Retinal volume map quantitative color map (top) and sectoral comparison to a normative database (below). Note that the blue foveal thinning is placed centrally.
FIGURE 8: Nasally displaced Stratus OCT macula raster scan. (A) Vertical macular B scan. Note that the foveal dip has increased reflectance in comparison with the well-centered scan shown in Figure 7B. (B) Thickness chart with the scan displaced nasally. (C) Retinal volume map quantitative color map (top) and sectoral comparison to a normative database (below). Note that the blue foveal thinning is displaced. In this case, the quantitative assessment of the macula overall has not been compromised, however, the foveal thickness is significantly different (in comparison with Figure 7D).

FIGURE 9: Normal ONH Scan from Stratus TD-OCT. (A) Infrared ONH image. (B) ONH parameter outlining a small cup-to-disc ratio (C/D). (C) ONH Analysis Results (D) Manually placed edges of retinal pigment epithelium (red-circles) allow for a computer generated disc (blue shaded area). (E) Vertical ONH B scan without any graphics shows a thick RNFL at the ONH.
FIGURE 10: Normal Optic Disc Cube 200x200 from Cirrus SD-OCT showing no progression. (A) RNFL Thickness Map. (B) En-face fundus image showing the location of the peripapillary circle scan location. (C) RNFL Tomogram extracted from the cube. (D) RNFL thickness profile compared to a normative database at the Temporal-Superior-Nasal-Inferior-Temporal (TSNIT) locations. (E) RNFL Thickness — Average, Quadrants, and Clock Hours. (F) Optic disc cube maps over 2 years showing no progression. These scan locations are automatically registered within the cube with the intent to have a consistent circle scan location in following progression. (G) Progression graph of average, superior, and inferior measurements. (H) Progression graph of RNFL thickness profile.

FIGURE 11: Normal Optic Disc Cube 200x200 from Cirrus SD-OCT, advanced visualization function. (A) CSLO fundus image showing the vertical (Purple line) and horizontal (blue line) scans available for viewing in the cube. (B) Vertical B Scan through the ONH. (C) Horizontal B Scan through ONH.
FIGURE 12: Normal Macular Cube 200x200 from Cirrus SD-OCT. (A) Macular thickness map. (B) Progression analysis map showing minimal change. (C) Horizontal B Scan from the macular cube.

FIGURE 13: Normal Optic Disc from Spectralis SD-OCT. (A) Confocal Scanning Laser Ophthalmoscopy ONH image (CSLO) overlay and background with a 3-Dimensional horizontal B scan through the ONH. (B) SLO ONH Image with peripapillary circle in green. (C) Sectoral RNFL measurements compared to a normative database. (D) Peripapillary Circle Scan. (E) RNFL thickness profile compared to a normative database.

FIGURE 14: Normal Macula Images from Spectralis SD-OCT. (A) Confocal Scanning Laser Ophthalmoscopy (CSLO) background green lines indicating the individual B scans. The brightest line is the scan location seen in the image below. (B) Horizontal B-Scan through the macula.
FIGURE 15: Normal Images from TopCon SD-OCT. (A) Peripapillary circle scan. (B) Vertical scan through ONH. (C) Macular scan.

FIGURE 16: Normal Images from RTView SD-OCT. (A) En-face ONH Image. (B) 3-Dimensional horizontal ONH scan cube data with CLSÖ overlay. Green line in (A) indicating location of scan. (C) ONH scan. (D) Peripapillary circle scan. (E) Thickness map of ONH compared to a normative database. (F) RNFL profile compared to a normative database. (G) Horizontal cross-line scan of macula. (H) Vertical cross-line scan of macula. (I) Ganglion Cell Complex (GCC) Scan of the macula with thickness map (left) and significance map (right).
TAKE HOME POINTS
1. Use OCT scans with a high quality signal strength.
2. Use OCT scans with good alignment around the ONH and on the macula.
3. It is beneficial to analyze data using the normative database.

CASE 2: GLAUCOMA — THE FOCAL DEFECT WITH EXCELLENT CORRESPONDENCE BETWEEN STRUCTURE AND FUNCTION
This was the left eye of a 57 year old female with normal tension glaucoma treated with Lumigan, Cosopt, and Alphagan. Best corrected visual acuity was 20/30 wearing a prescription of +0.75+0.50x90 and the IOP was 11 mm. The anterior segment examination was normal with wide open angles. The dilated fundus exam revealed an ONH with C/D = 0.85x0.6 with no other abnormalities (Fig. 19 A).

Red-free photography reveals a RNFL wedge defect at 4:00 (Figure 19B black arrows). Humphrey visual fields (HVF) showed a superior nasal step and superior paracentral scotoma (Figure 20).
Imaging with OCT, both TD (Fig. 21-23) and SD (Fig. 24) confirm this defect. Confocal scanning laser ophthalmoscopy (CSLO) and Scanning Laser Polarimetry also confirms this defect (Fig. 25 A and B, respectively).

**FIGURE 19:** Color disc photo (left) and Red-Free photo (right) with discoloration indicating an area of defect (between black arrow), better seen in the red-free photo.

![Color disc photo (left) and Red-Free photo (right) with discoloration indicating an area of defect (between black arrow), better seen in the red-free photo.](image)

**FIGURE 20:** HVF showing visual fields with a superior nasal step and superior paracentral scotoma. Grey scale (left) and pattern deviation (right). Glaucoma Hemifield Test (GHT) is outside of normal limits, visual field index (VFI)= 80%, mean deviation (MD)=-4.66 dB with p<0.5%, pattern standard deviation (PSD)=8.63dB with p<0.5%.

![HVF showing visual fields with a superior nasal step and superior paracentral scotoma. Grey scale (left) and pattern deviation (right). Glaucoma Hemifield Test (GHT) is outside of normal limits, visual field index (VFI)= 80%, mean deviation (MD)=-4.66 dB with p<0.5%, pattern standard deviation (PSD)=8.63dB with p<0.5%](image)

**FIGURE 21:** Images from Stratus TD-OCT Peripapillary Circle Scan. (A) B Scan showing focal RNFL inferiortemporal thinning (white arrow). (B) RNFL thickness profile comparison to a normative database confirming the inferiortemporal defect seen in (A). (C) Clock-hours (left) and quadrants (right) comparison to a normative database, again confirming the finding in (A).

![Images from Stratus TD-OCT Peripapillary Circle Scan. (A) B Scan showing focal RNFL inferiortemporal thinning (white arrow). (B) RNFL thickness profile comparison to a normative database confirming the inferiortemporal defect seen in (A). (C) Clock-hours (left) and quadrants (right) comparison to a normative database, again confirming the finding in (A)](image)

**FIGURE 22:** Stratus OCT macula raster scan. (A) Macular B scan at 330 degrees. Note the thin RNFL indicated by the white arrow. (B) Thickness chart – overall retinal thickness compared to a normative database. (C) Retinal volume map quantitative color map (left) and sectoral comparison to a normative database (right).

![Stratus OCT macula raster scan. (A) Macular B scan at 330 degrees. Note the thin RNFL indicated by the white arrow. (B) Thickness chart – overall retinal thickness compared to a normative database. (C) Retinal volume map quantitative color map (left) and sectoral comparison to a normative database (right)](image)
FIGURE 23: Stratus OCT Images (A) Optic Nerve Head Map. Black arrow indicating where the neuroretinal rim is thinnest, 4:00. (B) Radial B Scan through ONH 4:00 with manually placed edges of retinal pigment epithelium (red-circles) allow for a computer generated disc (blue shaded area). (E) Identical B scan as (B) without any graphics.

FIGURE 24: Images from RTView SD-OCT (A) "NHM4" ONH Scan showing a neuroretinal rim thinnest inferiorly. (B) ONH Scan with RNFL sector measurements along the 3.45mm diameter peripapillary circle. (C) RNFL Thickness Profile along the 3.45 mm circle. (D) Vertical Crossline through the macula showing decreased reflectance of the inferior RNFL.
TAKE HOME POINTS

1. Defects in the RNFL are displayed in the visual field inverted and reversed.
2. Red free photos are the best type of photo to view a focal neurofiber bundle defect.
3. The peripapillary circle, ONH, and macula scans can all provide information about RNFL wedge defects.

CASE 3: ADVANCED GLAUCOMA – THE CENTRAL ISLAND

This was the right eye of a 56 year old male with primary open angle glaucoma (POAG) treated with a trabeculectomy. All images are taken after the surgical treatment. Best corrected visual acuity was 20/30 and the IOP was 14 mm. The anterior segment examination was normal other than a flat bleb without leak superiorly and a patent peripheral iridotomy. The dilated fundus exam revealed an ONH with a barely perceptible neuroretinal rim (C/D = 0.99) with no other abnormalities. Humphrey visual fields (HVF) showed a severely depressed field with only central vision spared (Figure 26).

Imaging with OCT, both TD (Fig. 27) and SD (Fig. 28) confirm this defect. Confocal scanning laser ophthalmoscopy (CSLO) and Scaning Laser Polarimetry also confirms this global defect (Fig. 30 and 31, respectively). The macula RNFL thickness remains normal (Figure 29), corresponding with the remaining central vision.
FIGURE 28: (A) Optic Disc Cube 200x200 from Cirrus SD-OCT. (A) RNFL Thickness Map displays global thinning (top). En-face fundus image showing thinning most prominent superiorly and inferiorly (bottom). (B) RNFL Thickness – Average (top), Quadrants (middle), and Clock Hours (bottom). (C) RNFL Tomogram extracted from the cube. (D) RNFL thickness profile compared to a normative database at the TSNIT locations.

FIGURE 29: Macular Cube 200x200 from Cirrus SD-OCT. (A) Macular thickness map displaying that the macular has been spared from the otherwise global RNFL damage. (B) Horizontal (top) and vertical (bottom) B scans from the macular cube. (C) 3D segmentation of the macula showing the green circular island of retinal thickness at the macula surrounded by sea of thin (blue) retina.

FIGURE 30: CLSO Moorfields Regression Analysis outside normal limits for each sector.
TAKE HOME POINTS
1. The RNFL thickness “bottoms out” at 40 microns in severe damage.
2. Although the TD- and SD-OCT are not quantitatively identical, they can both provide into a RNFL defect location and severity.

CASE 4: GLAUCOMA — GLOBAL PROGRESSION
This was the left eye of a 52 year old female with juvenile glaucoma secondary to juvenile rheumatory arthritis. She was treated with a trabeculectomy in 2004. She also has ocular rosacea and is psuedophakic. All images are taken after the surgical treatments. From 2005 to 2009 she progressed globally both structurally by OCT and functionally by HVF.

From 2005–2009, the patient’s exam remained stable. Best corrected visual acuity was 20/30 and the IOP was 12 mm Hg, and remained stable without drops. External exam was notable for telangiectasis on the lids. The anterior segment examination was normal other than a flat bleb without leak superior and a patent peripheral iridotomy. The posterior chamber intraocular lense was in place. The dilated fundus exam revealed a pale ONH with a thin neuroretinal rim (C/D = 0.9) with no other abnormalities.

Red–free photography clearly shows a loss of the neurofiber layer from 2005 to 2009. In 2005, clear neurofiber bundles are visualized following the vascular arches (Figure 32 B). In 2009, these striations have disappeared and the shadows of choroidal vessels are clear (D, between white arrows).

In 2005 and 2009, HVF showed significantly depressed fields with both superior and inferior arcuate scotomas and superior and inferior nasal steps. (Figure 33).

Glaucoma progression analysis showed a significant VF deterioration in the superior and inferior nasal step areas. (Figure 34A). The VFI analysis shows non–significant progression (Figure 34B).

Imaging with TD–OCT (Figure 35) shows a significant progression globally from 2005 to 2009 (Figure 36). The RNFL thins much more than the HVF would suggest.

The macula RNFL thickness remains normal (Figure 37), corresponding with the remaining central vision.
FIGURE 33: HVF grey scale (left) and pattern deviation (right) from 2005 (A and B) and 2009 (C and D) showing visual fields with a superior and inferior nasal step as well as a superior and inferior arcuate. In 2005, GHT is outside of normal limits, VFI = 77%, MD = -9.82 dB with p < 0.5%, PSD = 7.28 dB with p < 0.5%. In 2009, GHT is outside of normal limits, VFI = 73%, MD = -11.53 dB with p < 0.5%, PSD = 8.13 dB with p < 0.5%.

FIGURE 34: Glaucoma progression analysis (A) showed a significant VF deterioration in the superior and inferior nasal step areas. The VFI progression analysis shows non-significant progression (B).

FIGURE 35: Stratus OCT TD-OCT Images in 2005 (A, C, and E) and 2009 (B, D, and F). Images (A) and (B) show the circumpapillary B scan in 2005 and 2009, respectively. Comparing (A) and (B) one can see the RNFL thinning globally. Images (C) and (D) show the RNFL thickness profile comparison to a normative database in 2005 and 2009, respectively. Images (E) and (F) show clock-hours (left) and quadrants (right) in comparison to a normative database in 2005 and 2009, respectively.
1. OCT is a tool that is able to quantify progression, even when a clinical fundus exam remains stable.

**CASE 5: GLAUCOMA — “PREPERIMETRIC”**

This was the right eye of a 70 year old female with a history of ocular hypertension since 1994, referred to the glaucoma service in 2004 after a structural defect was seen on imaging. No visual field defects appeared until 2006. She was treated in 2008 and 2009 with Selective Laser Trabeculoplasty.

Best corrected visual acuity was 20/20 and the IOP was recorded as 24 mm Hg in 2004 and 13 mm Hg in 2009. The anterior segment examination was normal with open angles. The dilated fundus exam revealed an ONH with C/D = 0.9x0.8 in 2004 and 0.9x0.9 in 2009 with no other abnormalities (Figure 38 A and B, respectively).

Humphrey visual fields (HVF) in 2004 show a normal field and in 2009 shows a superior nasal and a superior arcuate scotoma. (Figure 39 A and B, respectively).

Imaging with TD–OCT (Figure 41) displays a progressing inferior RNFL defect from 2004–2009. The RNFL changes are significant and progressive (Figure 42). Confocal scanning laser ophthalmoscopy (CSLO) confirmed this defect in 2004 (Fig. 45).

Imaging of the macula with OCT, both TD (Fig. 43) and SD (Fig. 44) also show an inferior defect. Figure 44 displays the progressive changes from 2006–2009.
FIGURE 38: Color ONH Photographs in 2004 (A) and 2009 (B). Note the baring of the lamina cribrosa inferiorly from and the superior neuroretinal thinning 2004 to 2009.

FIGURE 39: HVF from 2004 and 2009. HVF grey scale (left) and pattern deviation (right) from 2004 (A) and 2009 (B). In 2004, GHT is outside of normal limits, VFI= 100%, MD=+0.46 dB and PSD=1.78dB. In 2009, GHT is outside of normal limits, VFI=94%, MD=-2.73 dB with p<2%, and PSD=3.82dB with p<0.5%.

FIGURE 40: Glaucoma progression analysis from 2004-2009 (A) showed a significant VF deterioration in the superior nasal step area. The VFI progression analysis from 2004-2009 shows non-significant progression (B).

FIGURE 41: Stratus OCT TD-OCT Images in 2004 (A, C, and E) and 2009 (B, D, and F). Images (A) and (B) show the circumpapillary B scan in 2004 and 2009, respectively. Comparing (A) and (B) one can see the RNFL thinning inferiorly and inferiortemporally (between white arrows). Images (C) and (D) show the RNFL thickness profile comparison to a normative database in 2004 and 2009, respectively. Images (E) and (F) show clock-hours (left) and quadrants (right) in comparison to a normative database in 2004 and 2009, respectively.
FIGURE 42: Stratus TD-OCT Progression Analysis. (A) RNFL Profiles color coded by date (top) and graph of average RNFL thickness (bottom) showing a significant rate of change. In between the black arrows, the graph highlights the inferior area that thins progressively from the first visit (black line) to the last visit (red line). (B) Dates of scans color coded along with signal strengths and quantitative measurements of each scan.

FIGURE 43: Macular Scan from Stratus TD-OCT. (A) Vertical macular B Scan. (B) Retinal Thickness Chart. (C) Retinal Thickness Map. The macula in this case shows some inferior thinning.
TAKE HOME POINTS

1. OCT is capable of detecting damage to the RNFL before functional change occurs.

2. OCT is a tool that is able to quantify progression, even when a clinical fundus exam remains stable.

3. Some progression analyses are very useful in visualizing damage, especially for explaining to patients.

CASE 6: GLAUCOMA — FLUCTUATING FUNCTION BEFORE STRUCTURE

This was the left eye of a 75 year old male with a history of ocular hypertension vs. POAG since 2000 treated with Brimonidine-Timolol drops. A small focal superonasal scotoma appeared from 2002–2005, disappeared from 2006–2008, and reappeared in 2009 with no overall progression (Figure 46). Until 2006 when the OCT showed a clock-hour defect at 5:00, this spot was considered a patient-dependent error or lid line mark. In retrospect, this mark was indicative of impending corresponding structural changes.

Best corrected visual acuity was 20/25 and the IOP was recorded as 22 mm Hg in 2005 and 28 mm Hg in 2009. The anterior segment examination was normal with open angles. The dilated fundus exam revealed an ONH with C/D = 0.8 in 2005 and 0.9 thinnest inferiorly in 2009 with no other abnormalities. In 2006, a disc hemorrhage could be seen at 5:00 (Figure 45).

Imaging with OCT, both TD (Fig. 48) and SD (Fig. 49) display a progressive 5:00 defect (Figures 47 and 49).

FIGURE 45: Other imaging modalities confirming the pre-perimetric inferior defect in 2004 (A) CSLO. (B) SLP.
FIGURE 46: HVF from 2002-2009. (A) HVF grey scale (top) and pattern deviation (bottom) shows a fluctuating focal superior scotoma. (B) VFI progression shows no progression.

FIGURE 47: Stratus TD-OCT Progression Analysis. (A) RNFL Profiles color coded by date (top) and graph of average RNFL thickness (bottom) showing a significant rate of change. The black arrow indicates the inferior area that thins progressively from the first visits (black/purple line) to the last visit (dark blue line). (B) Dates of scans color coded along with signal strengths and quantitative measurements of each scan.

FIGURE 48: Stratus OCT TD-OCT Images in 2004 (A, C, and E) and 2008 (B, D, and F). Images (A) and (B) show the circumpapillary B scan in 2004 and 2009, respectively. Comparing (A) and (B) one can see the RNFL thinning inferiorly and inferiortemporally (between white arrows). Images (C) and (D) show the RNFL thickness profile comparison to a normative database in 2004 and 2009, respectively. Images (E) and (F) show clock-hours (left) and quadrants (right) in comparison to a normative database in 2004 and 2009, respectively.
TAKE HOME POINTS

1. Beware of misleading HVF. Rely more on VF progression analyses, as they necessitate a greater number of exams.

2. Sometimes a focal scotoma will come and go because it is patient-dependent. OCT provides a reproducible, quantitative measurement that is less patient-dependent.

3. VF changes may occur before changes are seen on OCT.
CASE 7: GLAUCOMA — STABLE HEMIFIELD STRUCTURAL DAMAGE WITH BOTH STABLE AND FLUCTUATING FUNCTIONAL CHANGES

This was the right eye of a 65 year old female with a history of POAG treated with trabeculectomy in 2006. All images are taken after the surgical treatment, 2007–2009.

Best corrected visual acuity was 20/20 and the IOP was 6 mm Hg, and remained stable without drops. The anterior segment examination was normal other than a superior avascular bleb without leak and a patent peripheral iridotomy at 1:00. The dilated fundus exam revealed an increased cupping from 2007–2009 C/D = 0.8 to 0.9 with no other abnormalities.

From January 2007–February 2009, HVF displayed a dense inferior nasal step and arcuate scotoma. It also seemed that the patient’s glaucoma had progressed functionally to include both a superior nasal step and arcuate scotoma. However, when the patient returned in September 2009, the superior defects nearly disappeared.

Imaging with OCT, both TD (Fig. 52) displayed a stable RNFL thickness through this time period (Figures 53). Other SD–OCT technologies showed similar B scan profiles (Figures 54–57).

FIGURE 50: Color ONH Photographs in 2009.

FIGURE 51: HVF from 2007-2009. (A) HVF grey scale (top) and pattern deviation (bottom) shows a fluctuating superior nasal step and arcuate scotoma. (B) VFI progression shows no progression.

FIGURE 52: Stratus OCT TD-OCT Images in 2009 and progression analysis. Image (A) shows the circumpapillary B Scan. Image (B) shows the RNFL thickness profile in comparison to a normative database. Image C shows clock-hours (left) and quadrants (right) in comparison to a normative database. (A)-(C) all correspond with HVF with more superior RNFL structural damage leading to a dense inferior defect.
FIGURE 53: Stratus TD-OCT Progression Analysis. (A) RNFL Profiles color coded by date (top) and graph of average RNFL thickness (bottom) showing no change. (B) Dates of scans color coded along with signal strengths and quantitative measurements of each scan. Note, how stable the measurements stay throughout the time period.

Rate of change: 2.013 +/- 4.135 μm/year*  
Statistically not significant P > 5%

<table>
<thead>
<tr>
<th>Date</th>
<th>SS,Q</th>
<th>AVG</th>
<th>SUP</th>
<th>INF</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/ /2007 (N=3)</td>
<td>7</td>
<td>51.14</td>
<td>51.00</td>
<td>70.00</td>
</tr>
<tr>
<td>10/ /2008 (N=3)</td>
<td>7</td>
<td>53.68</td>
<td>53.00</td>
<td>72.00</td>
</tr>
<tr>
<td>2/ /2009 (N=3)</td>
<td>7</td>
<td>51.92</td>
<td>51.00</td>
<td>70.00</td>
</tr>
<tr>
<td>9/ /2009 (N=3)</td>
<td>7</td>
<td>55.88</td>
<td>56.00</td>
<td>70.00</td>
</tr>
</tbody>
</table>

FIGURE 54: Optic Disc Cube 200x200 from Cirrus SD-OCT. (A) RNFL Thickness Map. (B) En-face fundus image showing the location of the peripapillary circle scan location and coloration based upon deviation from a normative database. (C) RNFL Tomogram extracted from the cube. (D) RNFL thickness profile compared to a normative database at the TSNITlocations. (E) RNFL Thickness – Average, Quadrants, and Clock Hours.

FIGURE 55: RTView SD-OCT NHM4 ONH Scan. (A) neuroretinal rim thinnest inferiorly. (B) ONH Scan with RNFL sector measurements along the 3.45mm diameter peripapillary circle. (C) RNFL Thickness Profile along the 3.45 mm circle.
TAKE HOME POINTS

1. Again, beware of misleading HVF — even large areas can fluctuate. Do not judge a single VF in isolation of the others that preceded it.

2. Currently, the various OCT technologies are not quantitatively comparable to one another.

3. OCT is an excellent quantitative, objective, and reproducible technology to monitor progression in glaucoma, or lack thereof. This statement is especially poignant in clinical management decisions.

CME ANSWERS

1. Retinal Nerve Fiber Layer (RNFL) thickness, ganglion cell complex (GCC). Optic nerve head parameters (ONH) may be useful as well, but there is insufficient evidence base to validate at this time.

2. Circumpapillary Scan, Macular Scan, and ONH Scan.

3. Increase in scanning speed enabling 3D imaging, improved resolution, post-processing capabilities, increased reproducibility, and better sensitivity and specificity in disease detection.

REFERENCES


LEARNING OBJECTIVES

1. Understand the linear relationship between retinal nerve fiber layer thickness and corresponding visual field areas of sensitivity.

2. Understand the limitations of using the retinal nerve fiber layer thickness to diagnose and monitor optic nerve disorders.

3. Understand the advantages and disadvantages of using the retinal ganglion cell layer thickness determined by OCT for diagnosis and management of optic neuropathy.

CME QUESTIONS

1. Which of the following factors may confound the accurate OCT determination of RNFL thickness for diagnosing optic nerve damage?
   a) Blood vessels
   b) Proliferation of glial elements in the retina
   c) Scan signal to noise
   d) Developmental differences in the distribution of axon bundles in the retina
   e) all of the above

2. Which of the following clinical conditions is likely to show the highest correlation between structure and function using OCT?
   a) compressive optic neuropathy
   b) NAION after 6 months
   c) optic neuritis after 6 months from the acute attack
   d) visual field loss in a patient with idiopathic intracranial hypertension
   e) all of the above

3. Which of the following factors may significantly confound the correlation between ganglion cell layer thickness and corresponding locations of visual sensitivity?
   a) the number of ganglion cell layers in the normal retina at the locations being evaluated
   b) peripheral field location of damage
   c) spatial variability in the mapping of ganglion cell location to corresponding visual field
   d) extent of visual field damage
   e) all of the above

KEY WORDS

Optical Coherence Tomography
Retinal Nerve Fiber Layer
Ganglion Cells
Glaucoma
Anterior Ischemic Optic Neuropathy
Optic Neuritis

Most clinicians, especially neuro-ophthalmologists and glaucoma specialists, have been trying to understand whether the information yielded by optical coherence tomography is really helping them to improve upon the clinical care of their patients. In this context, clinical decision-making has mainly focused on the status of the retinal nerve fiber layer (RNFL) thickness in relation to the threshold sensitivity of the corresponding area of visual field (see review, reference 1). Theoretically, it is expected that the degree of thinning of the RNFL will have a meaningful correlation with optic nerve function in a patient with loss of axons\textsuperscript{2-4} and less correlation of structure with function in locations where axons are still intact, but not functioning. In the latter case, either a return of function may still be possible, as in the case with some eyes with compressive optic neuropathy\textsuperscript{5}, acute optic neuritis\textsuperscript{6-9}, or ischemic optic neuropathy. Alternatively, the axons may have undergone irreversible dysfunction but not enough time has elapsed to produce atrophy and thinning of the RNFL\textsuperscript{1}. 
The clinical interpretation becomes even more difficult in the setting of optic disc edema associated with visual field loss, since there may be swelling of some axons with atrophy of neighboring axons, confounding the relationship between RNFL thickness and corresponding visual field sensitivity, as long as axon swelling is present and atrophy is not yet complete. Another potential confounding variable is the status of other components that make up the thickness of the RNFL, besides axons, such as blood vessels and glial elements, which may influence the measured thickness of the RNFL.

Attempts to quantify the relationship between structure and function between RNFL thickness and visual threshold at corresponding locations have discovered that there is a correlation (primarily studied in glaucoma and anterior ischemic optic neuropathy), but not as great as one would expect (refs). Factors such as measurement variability in both visual threshold and in RNFL thickness, the influence of non-neuronal elements on the RNFL thickness such as blood vessels and glial elements, and the inter-individual variation in mapping of RNFL bundles to their corresponding area of the visual field all confound the correlation in an individual patient. We have recently reviewed this topic and have provided evidence for a linear model relating visual threshold (unlogged) and RNFL thickness in glaucoma and AION. This is depicted in Fig 1 in semi-log plots.

While the relationship between RNFL thickness and visual field sensitivity appears to correspond to a linear model, there are still between and within subject components of measurement variability that impose limitations of this framework and its application to individual patients (see Figure 2). In addition, the dynamic range of both the RNFL and threshold sensitivity and their associated measurement variability limit meaningful relationships to be explored once 10 decibels of threshold loss have been exceeded or if the RNFL thickness drops below 60 microns for arcuate field loss.

Figure 2: The ellipses are the 95% confidence boundaries of the linear model of structure vs function with variability component shown for different glaucoma disease states, d, expressed in decibels of field loss. The 95% ellipses for the combined within- and between-individual variability (green), for between-individual variability excluding within-individual variability (red), and for within-individual variability excluding between-individual variability (blue) are shown for six levels of decibel visual field loss (from reference 4 with author permission).

In glaucoma studies, the RNFL thickness has been shown to have a very good sensitivity and specificity for diagnosing glaucoma, using Receiver-Operator Characteristic curve analysis (ROC). It is important to keep in mind that such analyses are always influenced by the criteria that are chosen as the gold standard for the presence or absence of the disease, the characteristics of the population being studied in terms of the distribution of severity of damage in the population included, and whether structure (disc appearance) or function (visual field sensitivity and the pattern of loss) is used as the criteria for the presence of glaucomatous or optic nerve disease.

A great deal of research has also been directed towards using the RNFL thickness to detect progression of glaucomatous damage over time (refs). Most of these studies have applied techniques that have also been used to study progression of visual field loss, namely a) significant change in RNFL status at a given time point from a prior baseline measurement or b) linear regression analysis of RNFL thickness over time. The main problems encountered in detecting progression using these
approaches are measurement variability and using population statistics to determine what constitutes a significant change over time. Individuals appear to vary considerably in their measurement variability, so applying population statistics (defining the variability of a given patient by applying the variability from a population of patients) to a given patient may not be optimal for individualizing the analysis of progression for a given patient. In addition, defining a statistically significant change over time may not always equate with what is a clinically significant change — one that would warrant a deviation in treatment. Because the rate of glaucomatous visual field progression varies considerably among treated and untreated patients and the rate is, in general, slow, the challenge in the future will be to identify as early as possible which patients are at the most risk for progression and focus aggressive treatment on those patients while not applying the same treatment to patients who are at low risk for significant progression over their remaining life expectancy.

For neuro–ophthalmology, the OCT landscape for optic nerve diseases other than glaucoma pose similar problems. These mostly encompass the following disorders and focus on questions regarding the application of OCT to diagnosis and treatment:

1. **Multiple Sclerosis**: In this setting OCT is being used to help substantiate the diagnosis of multiple sclerosis, determine whether OCT can be used to monitor the course and treatment of demyelinating disease and predict which patients are likely to progress at a faster rate, requiring a more tailored treatment approach. There is also evidence that total macular thickness may also reflect neuronal loss in multiple sclerosis. The main interest at present is whether acute optic neuritis is a good model for evaluating the efficacy of new CNS multiple sclerosis treatment strategies, such as the use of neuro–protectants and whether the use of OCT is a valid surrogate for modeling the status of multiple sclerosis and treatment strategy.

2. **Non–arteritic anterior ischemic optic neuropathy (NAION)**: Structural features on OCT are being identified (such as neural opening size in the sclera) which might predict which patients are at the most risk for progressive visual field loss during the acute phase of NAION and who may respond to treatment interventions during the first 2 weeks (e.g. steroids). It may be possible to use OCT to help identify patients that are most likely to benefit from treatments aimed at preserving axons.

3. **Compressive optic neuropathy**: The presumption is that the greater number of axons that are present at the time of diagnosis, the higher potential for visual recovery if decompression is successful. Here the confounding variables are how much time must elapse before axonal degeneration is detectable on OCT at the time of diagnosis and how many neurons/axons are required to support adequate visual function which may influence treatment decisions?

4. **Papilledema**: When the optic nerve appears swollen, the main questions applicable to OCT concern whether true papilledema is present vs. pseudopapilledema, whether the change in optic disc edema over time can be better quantified using thickening of the RNFL with OCT compared to the fundus appearance of the optic nerve and whether axon loss can be detected while the disc is still swollen and differentiated from a reduction in RNFL thickness due to lowering of intracranial pressure.

5. **Differentiation of optic neuropathy from retinopathy and identifying disorders in which both are present**: OCT scans of other portions of the posterior pole besides the RNFL can be very revealing. For example, acute or subacute visual field loss with a thickened macula on OCT but without obvious evidence of retinal edema on fundus exam may help point the diagnosis more correctly toward a branch or central retinal artery occlusion (CRAO), and away from anterior or posterior ischemic optic neuropathy, inflammatory, or compressive optic neuropathy. In the chronic state, an abnormally reduced total macular thickness keeping company with a thinned RNFL and pale nerve may also help make the diagnosis of a previous retinal artery occlusion, without requiring an electrotoretinogram (ERG) or neuro–imaging. Another example is a patient with possible neuroretinitis and persistent visual field loss; the combination of an OCT scan of the peripapillary RNFL and macula scan may help reveal the layer of the retina which is most likely to be the source of pathology explaining the visual field loss.

Most ophthalmologists use the macula OCT to diagnose disorders causing loss of the photoreceptors in the outer retina or disorders causing fluid accumulation in the retina (e.g. cystoid macular edema, diabetic macular edema, vitreal traction, perifoveal telangiectasia, choroidal neovascular membrane), or macular holes. Such patients may make their way into a neuro–ophthalmology clinic and a macular OCT may be an important diagnostic tool to narrow the differential and reduce cost of a work–up.

The factors discussed above pose limitations on relating the retinal nerve fiber layer to visual threshold and axon loss. This has prompted an interest in going to the source of the axons – the soma of retinal ganglion cells, which predominate in the macula. Here the question is whether the ganglion cell layer can be accurately quantified within the macula scan using current OCT technology and whether a change in the number of viable neurons can accurately be detected with current software. This also presupposes that the ganglion cells in the macula are adequate surrogates for disease affecting the visual field outside of the macula.
Segmentation of the ganglion cell layer within the central macula with spectral domain OCT has a number of potential advantages:

1. The retinal ganglion cells are densest in the macula and form a stratified multi-cellular layer within the central 6 degrees of visual field. Therefore, loss of axons and the corresponding soma in this location is likely to cause a thinning of the retinal ganglion cell layer.

2. The lack of large retinal vessels in this location makes their confounding contribution to the thickness of the ganglion cell layer very minimal, compared to the peripapillary retina, where they do influence the RNFL measurement.

3. The mapping of visual field location to corresponding ganglion cell soma is less complicated than the situation with the RNFL bundles and may show less inter-individual developmental variability. Simplistically, a focal light in the macula activates the ganglion cells directly underlying it. In the foveal and perifoveal location this is not strictly the case and some modification has to be made in this area of the visual field due to displaced ganglion cells.

4. Recent advances in OCT image analysis using both manual\textsuperscript{14} and automated analysis in three dimensions\textsuperscript{15,16} have provided a potential solution for delineation of the different neuronal layers in the macula (Figures 3–4).

5. Preliminary attempts to quantify the correlation between visual threshold and retinal ganglion cell thickness in the macula appear to subjectively correlate with the spatial pattern of visual field loss in the macula in patients with glaucoma (Figure 5) and anterior ischemic optic neuropathy. However, a quantitative correlation between ganglion cell thickness and corresponding overlying visual threshold has not yet been reported in detail.

Challenges associated with OCT analysis of the macula that need to be overcome before clinical monitoring of optic nerve function is useful:

1. Total macula thickness is a measurement that is not likely to be specific and sensitive enough to detect small changes in the ganglion cell layer associated with optic neuropathy. This is why segmenting the different layers is likely to be a better approach.
2. Current commercially available OCT and associated software are not capable of segmenting the ganglion cell layer in three dimensions. At best, one manufacturer (Optoview) purports to segment the inner layers of the retina of the macula as a neural complex layer (RNFL, ganglion cell layer and inner plexiform layers), but this software analysis has not yet been rigorously validated. Recently Don Hood and colleagues reported to have manually segmented two-dimensional line scans through the macula and have shown correlation of thinning of the ganglion cell+inner plexiform layer with corresponding loss of visual threshold in glaucoma, so this approach does have promise. Our group has reported automated segmentation of retinal layers using a 3D graph search approach applied to volume OCT scans, as shown in Figures 3–5.

3. Outside of the central 6 degrees of the macula, the ganglion cell layer is less of a multi-cellular layer. In areas where there is only a single layer of ganglion cells it is not known if loss of soma will cause a measurable, significant thinning of the cellular layer or whether it will just be replaced by glial and Mueller cells, making structural thinning of the ganglion cell layer of the inner retina difficult to measure.

4. Focal peripheral visual field damage would be unlikely to affect the retinal ganglion cell layer in the macula, making it theoretically less sensitive to detection and monitoring of peripheral field pathology. On the other hand, most optic nerve diseases do show some degree of diffuse loss and although significant abnormalities in visual threshold may not be detected, there still may be a measurable decrease in retinal ganglion cell thickness in the macula, even though a visual field test may appear to show mainly extra-macular loss of sensitivity.

5. It is currently not known how much time it takes for a decrease in the thickness of the ganglion cell layer to occur after damage to the optic nerve at different distances from the globe. The time delay between permanent damage and atrophy of the ganglion cell layer would provide a framework for dating the time of injury.

In summary, recent improvements in OCT resolution and automated segmentation software has provided a means of relating visual pathway damage to structural changes in the RNFL and corresponding soma of the ganglion cells in the macula. Ganglion cell layer analysis in volume OCT data may provide yet another piece of the puzzle to understanding structure–function relationships and its application to diagnosis and monitoring of optic nerve and retinal diseases.

CME ANSWERS
1. e) all of the above; all of these factors may influence the ability to differentiate a normal RNFL from an abnormal thinning due to optic nerve damage
2. b) thinning of the RNFL reaches a maximum at 6 months following acute injury from AION. The other conditions may not show as good a correlation between structure and function.
3. e) all of the above.

REFERENCES


PLATEFORM PRESENTATION
GANGLION CELL LAYER VOLUME BY SPECTRALIS OPTICAL COHERENCE TOMOGRAPHY (OCT) IN MULTIPLE SCLEROSIS

Emma Davies¹, Dina Jacobs¹, James Wilson¹, Clyde Markowitz¹, Steven Galetta¹, Elliot Frohman², Peter Calabresi³, Laura Balcer¹

¹University of Pennsylvania School of Medicine, Philadelphia, PA, United States,
²University of Texas Southwestern Medical Center, Dallas, TX, United States,
³Johns Hopkins University School of Medicine, Baltimore, MD, United States

INTRODUCTION:
Anterior visual pathway neuronal loss in multiple sclerosis (MS) has been suggested by optical coherence tomography (OCT) measurements of macular volume. Software programs that segment retinal layers are used but not yet widely available. The purpose of this study was to pilot a manual method of estimating the retinal ganglion cell layer volume by Spectral-Domain OCT, and to explore the relation of this volume to visual function and prior history of optic neuritis (ON).

METHODS:
Patients with MS and control subjects underwent fast macular OCT scans (25 frames/eye) obtained with Spectral-Domain OCT technology. Ganglion cell layer volume was determined by manually outlining these structures for each frame of the OCT scan. Images were magnified by 400–800%; contrast was enhanced to maximize the accuracy of layer delineation. Visual function testing was performed using low-contrast (1.25% level) and high-contrast visual acuity (VA).

RESULTS:
Eyes of patients with MS (n=16, age 50±6.3 years) had a lower ganglion cell layer volumes than did control eyes (MS: 0.76 mm³ vs. controls: 1.06 mm³; p=0.0001, t-test). MS eyes with a prior history of ON had the greatest degree of ganglion cell layer thinning. Lower ganglion cell layer volumes were associated with poorer performance on tests of low-contrast letter acuity (r=0.60, p<0.001), but not VA (r=0.10).

CONCLUSION:
This exploratory study demonstrates thinning of the retinal ganglion cell and associated layers in MS eyes. This finding is most pronounced in the setting of a prior history of ON, consistent with the occurrence of neuronal in addition to axonal loss in this setting. Low-contrast acuity is more sensitive than high-contrast VA to ganglion cell layer loss in this small cohort. Ongoing longitudinal studies piloting segmentation software will define the temporal relation of neuronal to axonal degeneration in MS, ON, and other optic neuropathies.

REFERENCES:

KEY WORDS:
Multiple Sclerosis (MS), Optical Coherence Tomography (OCT), Ganglion Cell Layer, Visual Function

FINANCIAL DISCLOSURE: NONE
LEARNING OBJECTIVES
1. To understand how OCT helps identify maculopathy that may mimic optic neuropathy.
2. To understand how OCT can aid in the management of various optic neuropathies.
3. To understand some of the limitations of OCT and how to avoid misinterpretation of OCTs.

CME QUESTIONS
1. OCT can identify all but which of the following macular lesions that may not be apparent clinically?
   a. Occult outer retinopathy, including MEWDS
   b. Stargardt’s disease
   c. Cone dystrophy
   d. Solar maculopathy
2. OCT can clearly distinguish improvement of papilledema from evolution of papilledema into atrophic papilledema. True or False?
3. Nerve fiber layer analysis by OCT can distinguish mild papilledema from pseudopapilledema. True or False?

KEY WORDS
1. Optical Coherence Tomography
2. Occult Maculopathy
3. Optic Neuropathy
4. Papilledema
5. Optic Neuritis
6. Anterior Ischemic Optic Neuropathy

INTRODUCTION
I have been fortunate to have access to optical coherence tomography (OCT) since its inception thanks to collaboration between Joel Schuman and others at the New England Eye Center with Jim Fugimoto at M.I.T. At first, this appeared to be a tool primarily useful for retina specialists, but, as optic nerve analysis became more refined for the use in glaucoma, its use in other types of optic neuropathy became more apparent. However, there are still some difficulties with regard to this, which will be reviewed below. What turns out to be most useful in neuro-ophthalmic practice is the ability of OCT to identify and prove occult maculopathy mimicking optic neuropathy, and this has had a significantly positive impact on my practice.

HOW I USE OCT IN MY NEURO-OPHTHALMIC PRACTICE
Proving Maculopathy That May Mimic Optic Neuropathy
Years ago, the diagnosis of occult maculopathy mimicking optic neuropathy depended on subtle and often indirect findings. Frequently, this also required ruling out optic neuropathy, sometimes at significant expense. It was not unusual for neuro-ophthalmologists to become engaged in a dialogue with a retina specialist who insisted that a patient with unexplained visual loss had optic neuropathy, when the neuro-ophthalmologist was sure that the problem was indeed macular, but had no clear way of proving this. Central serous retinopathy was a common maculopathy, which could mimic optic neuropathy yet could easily be identified with fundus fluorescein angiography. However, now, with more refined OCT techniques, other retinal conditions mimicking optic neuropathy are more easily proven.

The diagnosis of macular hole and epiretinal membrane often required considerable discussion between neuro-ophthalmologists and retina colleagues in the past. Now macular hole is a favorite diagnosis for retina specialists now that it can be treated surgically. OCT reliably and consistently demonstrates macular holes and epiretinal membranes. Another group of conditions, now more easily identified using OCT, the occult outer retinopathies, includes multiple evanescent white-dot syndrome, acute zonal occult outer retinopathy, and acute idiopathic blind spot enlargement syndrome. These conditions are especially easy to identify with high-resolution OCT whereby the inner segment/outer segment junction is usually affected in the retinal areas corresponding to the clinical findings. These diagnoses are also made with more assurance using multifocal retinography. However, OCT is much easier and quicker for the patient and usually suffices.

We have also found that ultra-high resolution OCT helps in localizing the cause of microscotomas to the outer retina. However, we still do not have a better understanding of the pathophysiology of this condition. Hopefully, with more detailed OCT, the mechanism by which these micro scotomas occur will become apparent.

The structural findings in some patients with microscotoma that we see with OCT do resemble those which are seen with phototoxic maculopathy which can
result in a very discrete area of inner segment/outer segment loss in such individuals. It also resembles what is occasionally seen in patients with epiretinal membrane.\textsuperscript{12}

FIGURE 1. Inner segment/outer segment defect in a patient with a paracentral microscotoma.

Bilateral central visual loss in young people with apparently normal appearing retinas and optic nerves has been a diagnostic dilemma until recently. Frequently, these children have required a variety of rather expensive investigations. Although multifocal electroretinography can identify juvenile retinal degeneration or Stargardt’s disease when it does occur, OCT does show distinctive macular outer retinal changes early on, and I think OCT will become the standard way of making this diagnosis in the future.\textsuperscript{13} Multifocal electroretinography may be difficult in young children, although we have been able to use this approach in some individuals as young as six years of age. We have also found that OCT is as sensitive in identifying hydroxychloroquine retinopathy as multifocal ERG.\textsuperscript{14} OCT allows neuro-ophthalmologists to make diagnosis of occult maculopathy much more efficiently and, this has saved me time and has saved patients considerable expense.

FIGURE 2. Perifoveal inner segment/outer segment loss in a patient with Plaquenil retinal toxicity. Note also the presence of epiretinal membrane on the right portion of the inner retina.

OPTIC NEUROPATHY IN THE PRESENCE OF RETINOPATHY

OCT can identify optic neuropathy when there is nerve fiber layer loss, and this may be the first clue that there is an insidious optic neuropathy occurring such as with optic nerve sheath meningiomas. In individuals with mild decrease in visual acuity, mild visual field constriction, mild color vision loss, and subtle visual field constriction, finding nerve fiber layer thinning provides more objective evidence that there is an optic neuropathy that requires further investigation. We have been impressed with how optic nerve head analysis by OCT will identify optic neuropathy in the presence of a known maculopathy. Even though such individuals may have visual field characteristics that are more typical of optic neuropathy, such as bitemporal hemianopia, frequently a concomitant maculopathy makes interpretation of subjective psychophysical tests difficult. Finding characteristic nerve fiber layer changes on OCT does help motivate me at least to obtain MRI scans when a retinal surgeon sends me a patient in whom the possibility of an optic neuropathy coexisting with maculopathy arises.

FUNCTIONAL LOSS OF VISION

OCT can provide further objective evidence of normal structure in patients suspected of having functional visual loss. However, one must remember that retinal nerve fiber layer degeneration does take time to develop, and a normal RNFL thickness does not always rule out a compressive optic neuropathy. However, in patients who have had functional visual loss for many months or years, a normal RNFL thickness, along with a normal macular scan, is strong, objective evidence that there is no structural pathology accounting for visual loss that is likely functional in nature.

OPTIC NERVE SWELLING

We have attempted to use OCT to differentiate mild papilledema from pseudopapilledema. OCT can show optic nerve head drusen, and, when there are significant drusen, one would expect the retinal nerve fiber layer to be thin.\textsuperscript{15} However, in those individuals with congenitally crowded optic nerve heads, without significant drusen, we have been impressed that OCT shows thickening of the nerve fiber layer, similar to that which occurs in mild papilledema.\textsuperscript{16} Therefore, we now use OCT to observe such individuals with suspected pseudopapilledema over time, just the way we used to use photographs for this purpose. If the OCT does not show any change in the nerve fiber layer thickness over time, then we can assume that such individuals were born with crowded nerves and thicker nerve fiber layers. The finding of thickened nerve fiber layer on circumferential OCTs in patients with pseudopapilledema is not surprising, considering that there is axoplasmic flow stasis in these individuals, just as there is in those with true papilledema. Of course, one must remember that patients with pseudopapilledema can
develop increased intracranial pressure and these two conditions may occur simultaneously. Recently, one report showed evidence that peripapillary subretinal fluid may be seen exclusively in patients with pathologic optic nerve swelling either from increased intracranial pressure or from ischemic optic neuropathy. Perhaps this may be the best way to distinguish mild papilledema from pseudopapilledema in the future.\textsuperscript{17}

We also have been using OCT to followup patients with papilledema. However, the main problem with this has been in interpreting what appears to be normalization of the retinal nerve fiber layer thickness when there is concomitant optic atrophy, which also leads to reduction in the thickness of the nerve fiber layer over time. However, we have some indication that there may be a pattern of nerve fiber layer change, which may indicate that there is optic atrophy superimposed upon papilledema. When the thickness of the superior nerve fiber layer diminishes while the thickness of the inferior nerve fiber layer remains elevated, the likelihood of visual field loss appears to rise, indicating the onset of atrophic papilledema, rather than improvement in the papilledema.

One observation that OCT has allowed is the visualization of subretinal fluid in patients with papilledema.\textsuperscript{18} This may correlate with loss of visual acuity which is a reversible phenomenon. The degree of subretinal fluid in the foveal region seems to correlate with the degree of visual acuity loss, and, just as in patients with central serous retinopathy, the prognosis for recovery of visual acuity remains good and, in my practice, when there is loss of visual acuity and this can be demonstrated to be due to subretinal fluid by OCT, I do not feel that this is definitely an indication for urgent intervention surgically. The source of the fluid is not entirely clear. Because there is frequently a communication between the subfoveal fluid and the peripapillary subretinal fluid that we also described, the possibility that the fluid could be coming from the choroid remains the best possibility. There may be disruption of the connections between Bruch's membrane and the optic nerve which is disturbed because of the swelling of the nerve, allowing for serous fluid to leak under the retina in the peripapillary space and then, in some individuals, track into the subfoveal region.

Subretinal fluid has also been observed in patients with anterior ischemic optic neuropathy.\textsuperscript{19} We believe that, when there is loss of visual acuity in patients with AION associated with subfoveal fluid/fluid, this may have significant implications with regard to treatment. Patients with subretinal fluid from AION, like patients with subretinal fluid from papilledema, also have a good prognosis for spontaneous recovery of visual acuity as the subretinal fluid resorbs.

FIGURE 3. Foveal and peripapillary subretinal fluid in a patient with acute nonarteritic AION. The patient’s vision spontaneously recovered from 20/400 to 20/40 over 3 months.

VITREOPAPILLARY TRACTION
OCT has also been very useful in our practice in patients with suspected optic disc swelling due to vitreopapillary traction.\textsuperscript{20} Vitreopapillary traction may be difficult to prove by ophthalmoscopy alone. However, OCT clearly shows vitreous adhesions to the optic nerve head, and in some of these individuals, there may be simultaneous, vitreomacular traction. When the latter occurs, the resolution of the pseudopapilledema caused by vitreopapillary traction can be relieved surgically.

COMPRESSIVE OPTIC NEUROPATHY
There have been some interesting OCT findings in patients with compressive optic neuropathy.\textsuperscript{21, 22} However, from a practical point of view, we have not found OCT to be all that useful in managing patients with compressive optic neuropathy. We do not feel that OCT aids in the prognosis any more than ophthalmoscopic observation of the retinal nerve fiber layer does. Our main goal in managing patients with compressive optic neuropathy is to prevent any retinal nerve fiber layer loss, and visual field testing remains the main tool in identifying compressive optic neuropathy before optic atrophy develops. As opposed to patients with optic nerve head disease, glaucoma being the main example, visual field changes usually precede nerve fiber layer changes and we continue to follow all of our patients with compressive optic neuropathy primarily monitoring their visual fields.

OPTIC NEURITIS
From a practical point of view OCT is occasionally useful in managing patients with optic neuritis.\textsuperscript{23-29} Although OCT can serve as a biomarker for the progression of demyelinating disease, it may not always reflect the overall degree of demyelination occurring in such individuals. Certainly, OCT will be a useful in studies of the effectiveness of various drugs in the treatment of demyelinating disease from an investigational point of view, but for the day-to-day management of patients with MS, OCT is probably only going to be as useful as MRI scanning to monitor the overall condition of the patient. Although there have been reports of OCT helping to distinguish patients with neuromyelitis optica from those...
with multiple sclerosis, the degree of nerve fiber layer
dropout is reflected by the degree of visual loss
demonstrated by visual acuity testing or visual field
testing, so OCT so in and of itself is not all that useful in
that regard.

CAVEATS
Although OCT has become very useful in my practice over
the last several years, I try to remain aware of some of the
limitations of OCT. OCT can be normal in patients with
compressive optic neuropathy, and visual field testing
remains the most important diagnostic tool in the
diagnosis and followup of patients with compressive optic
neuropathy. OCT can be normal in patients with some
occult maculopathies, and multifocal electroretinography
may be needed to identify maculopathy in these patients
and to prevent extensive evaluations, searching for other
diagnoses. A bad OCT is like a bad MRI or a bad CT scan.
There may be errors in retinal nerve fiber layer analysis.
Sometimes the algorithm used by the OCT machine will
fail and false measurements of the retinal nerve fiber layer
or the macula may occur. It is important to check the
alignment of the circular scans when analyzing retinal
nerve fiber layer measurements. If the scan is not properly
placed which respect to the optic nerve head, inaccurate
measurements may follow. This is especially problematic
in patients with swollen optic nerves where the presence
of subretinal fluid and marked elevation of the nerve fiber
layer may provide measurements which are inaccurate
because they are out of the range of the normal algorithm.
Perhaps, in patients with optic nerve head swelling, a
larger diameter should be used for retinal nerve fiber layer
analysis. Also, there may be errors in macular analysis. To
avoid this, because most macular diagnoses rely on a
more qualitative evaluation of the OCT, I always obtain
line scans, which incorporate the optic nerve head and the
macula. This allows for a better view of the anatomic
details of the macula, which are not always clear on the
typical macular scans. OCT may identify concurrent optic
nerve and macular disease. Therefore, I image the macula
as well as the RNFL in every patient in whom I obtain OCT.

MY STANDARD PROTOCOL FOR OCT
My standard protocol is to obtain a retinal nerve layer
scan, a macula scan, and a line scan of the macula and
nerve. I have not found that the optic nerve head protocol
is useful in analyzing optic nerve disease, and I have very
little experience with this. Spectral domain OCT appears
better than time domain for evaluating macular disease.
However, the time domain appears to be more consistent
with regard to retinal nerve fiber layer analysis, especially
for serial analysis over time. High-speed ultra-high
resolution OCT is best for occult maculopathy, especially
for the occult outer retinopathies, and also in patients
with micro scotomas.

CME ANSWERS
1. C
2. False
3. False

REFERENCES
1. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang
22;254(5035):1178–81.
2. Fujimoto JG, Brezinski ME, Tearney GJ, Boppart SA, Bouma B,
Hue MR, et al. Optical biopsy and imaging using optical
optical coherence tomography of surgically closed macular
optical coherence tomography assessment of photoreceptors
in retinitis pigmentosa and related diseases. Am J Ophthalmol
2006;142:945–952.
coherece tomography in non-exudative age related macular
and standard resolution optical coherence tomography for
imaging of macular pathology and repair. Ophthalmol
2004;111:2033–43.
visualization of macular pathology with the use of ultrahigh-
resolution optical coherence tomography. Arch Ophthalmol
and 3-dimensional imaging of macular pathologies with
high-speed ultrahigh-resolution optical coherence
tomography chronic solar retinopathy. Am J Ophthalmol
ultrahigh resolution optical coherence tomography findings in
chronic solar retinopathy. Retin Cases Brief Rep
findings in solar retinopathy. Ophthalmic Surg Lasers Imaging
disruption secondary to posterior vitreous detachment as
visualized using high-speed ultrahigh resolution optical
Nov;125(11):1579–1580.
Visual Function in Stargardt’s Disease/Fundus Flavimaculatus
with Ultrahigh-Resolution Optical Coherence Tomography.
al. High-Speed Ultra-High-Resolution Optical Coherence
Tomography Findings in Hydroxychloroquine Retinopathy.
Arch Ophthalmol. 2007;125:775–780.


